Table 4.
Logistic regression analysis of factors associated with receipt of adjuvant chemotherapy among patients not receiving neoadjuvant chemotherapy
| Variable | OR a | 95% CI a | Adjusted P a |
|---|---|---|---|
| Age at diagnosis (years) | |||
| <50 |
Referent |
|
|
| 50 to 69 |
0.690 |
0.386 to 1.234 |
0.211 |
| ≥70 |
0.303 |
0.143 to 0.643 |
0.002 |
| Comorbidities | |||
| None |
Referent |
|
|
| One or more |
1.090 |
0.810 to 1.467 |
0.568 |
| Menopausal status | |||
| Premenopause |
Referent |
|
|
| Menopause |
1.374 |
0.778 to 2.428 |
0.274 |
| Residential status | |||
| Rural |
Referent |
|
|
| Urban |
1.398 |
1.058 to 1.846 |
0.018 |
| Tumor size | |||
| ≤2 |
Referent |
|
|
| >2 |
0.799 |
0.510 to 1.150 |
0.198 |
| Lymph node metastasis | |||
| Negative |
Referent |
|
|
| Positive |
1.383 |
1.057 to 1.809 |
0.018 |
| Distant metastasis | |||
| Negative |
Referent |
|
|
| Positive |
1.908 |
0.191 to 19.015 |
0.582 |
| Hormone receptor statusa | |||
| ER- and PR- |
Referent |
|
|
| ER + and/or PR+ | 1.425 | 0.981 to 2.070 | 0.063 |
aAdjusted using multivariate logistic regression model.
ER, estrogen receptor; PR, progestogen receptor; OR, odds ratios; CI, confidence intervals.